Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

ancial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

About Amylin PharmaceuticalsAmylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin is committed to delivering novel therapies that transform the way diabetes, obesity and related metabolic disorders are treated. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, Calif., and has a commercial manufacturing facility in Ohio. More information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or BYDUREON, and the revenues or royalties generated from these products, may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that the unaudited financial results set forth in this press release could differ materially from our year-end audited financial results; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results, may not be predictive of real world use or may not achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests, may not be submit
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Pa. , Sept. 22, 2014  Inovio ... today it has initiated a phase I clinical ... will evaluate the safety, tolerability, and immunogenicity of ... (HPV-6), which causes most aerodigestive cancers. ... throat, vocal cords, and parts of the esophagus ...
(Date:9/22/2014)... and NEW YORK , ... (OTCBB: ACCP), has signed an exclusive, global license ... development and commercialization of its proprietary plasma fractionation ... management team and its intention to strategically refocus ... and its plans to pursue a national listing ...
(Date:9/22/2014)... Sept. 22, 2014 Auxilium Pharmaceuticals, Inc. ... company, today announced that its Board of Directors ... conditional proposal from Endo International plc ("Endo") and, ... advisors, has unanimously determined it is not a ... merger agreement with QLT Inc. ("QLT") and has ...
Breaking Medicine Technology:Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Auxilium Provides Transaction Update 2Auxilium Provides Transaction Update 3Auxilium Provides Transaction Update 4Auxilium Provides Transaction Update 5Auxilium Provides Transaction Update 6
... DecisionView Inc., a leading provider of ... life sciences companies, today announced the release of ... flagship solution for patient enrollment planning, tracking and ... into site performance and cost projections, StudyOptimizer 4.3 ...
... 19, 2011 Reportlinker.com announces that ... available in its catalogue: ... http://www.reportlinker.com/p0358494/North-American-External-Defibrillator-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices ... state of the North American external ...
Cached Medicine Technology:DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting 2DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting 3North American External Defibrillator Market 2North American External Defibrillator Market 3North American External Defibrillator Market 4North American External Defibrillator Market 5North American External Defibrillator Market 6
(Date:9/22/2014)... percent of patients undergoing breast cancer surgery require additional ... cancerous tissue in the initial operation. However, researchers at ... tool they developed that will help surgeons better distinguish ... chances for repeat operations. , The ... 2014 in the Proceedings of the National Academy ...
(Date:9/22/2014)... South Asians living in Canada have a higher rate ... compared with while people, McMaster researchers have found. ... Canadian Medical Association Journal (CMAJ Open) and may ... the fastest-growing ethnic groups in the country is the ... Canada, comprising about three percent of the population. They ...
(Date:9/22/2014)... 2014 Quincy Bioscience, one of ... promotes National Self-Improvement Month this September. ... should have access to self-improvement resources, especially for ... demand for products that preserve health is growing ... For over six years, Quincy Bioscience has been ...
(Date:9/22/2014)... York, New York (PRWEB) September 22, 2014 ... associated with the use of power morcellators ( ... LLP notes a new report detailing the continued ... warnings from federal regulators that specifically discouraged these ... physicians believe that the potential cancer risks associated ...
(Date:9/22/2014)... CareFlight Air & Mobile Services of Miami ... N3+ Dauphin, the latest version of Airbus Helicopters outstanding ... at Miami Valley Hospital in Dayton, Ohio, ... helicopters. , “We have a lot of confidence in ... Emergency, Trauma, and CareFlight. “We’ve been operating Dauphins for ...
Breaking Medicine News(10 mins):Health News:The fine line between breast cancer and normal tissues 2Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... Discoveries are exciting but roadblocks remain, experts say , , ... future, people may routinely have doctors scan their personal ... help prevent, spot or treat a cancer. , "We ... a revolution in cancer care," said Dr. Len Lichtenfeld, ...
... With the Help of Leading Medical and Lifestyle Experts ... - the National Psoriasis Foundation is Empowering ... Expanded Web Resources, NEW YORK, Sept. 15 ... have a new resource. Today,the National Psoriasis Foundation officially ...
... disorder is widespread but can be prevented , FRIDAY, Sept. ... the diagnosis, management and prevention of a widespread, deadly lung ... 15 percent to 25 percent of adults over the age ... in the United States. It,s expected to become the fifth ...
... way to motivate the billion people in the world ... an overwhelming task, but a University of Houston professor ... his own. , Ioannis Pavlidis, a UH computer science ... have developed a computer game that translates physical activity ...
... Mozambique, Sept. 14 Aid provided by,The Prem Rawat ... 300 women and their families who were victims of ... After the flooding, caused by cyclones in this ... were displaced from their homes. The,Prem Rawat Foundation made ...
... 14 MAKO Surgical Corp., a,developer of minimally ... today that Frederic H. Moll, M.D.,has been named ... 24,2007. Dr. Moll has over 20 years ... co-founded Hansen Medical Inc. in September 2002 and,currently ...
Cached Medicine News:Health News:Genetics Hold Promise, Challenges for Cancer Care 2Health News:Genetics Hold Promise, Challenges for Cancer Care 3Health News:Genetics Hold Promise, Challenges for Cancer Care 4Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 2Health News:Empowerment Program Gets Patients on the PATH to Managing the Physical and Emotional Effects of Psoriatic Arthritis 3Health News:Experts Publish New Lung Disease Guidelines 2Health News:Weight loss game looking for 'NEAT-o' results 2Health News:The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique 2Health News:MAKO Surgical Corp. Names Frederic H. Moll, M.D. to Board of Directors 2
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... of German Craftsmanship have produced ... the world. Ocutek now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
... platform with integrated neck. Piston assembly ... an internal spring to recoil back ... Block fits into precision milled cavity ... sized 6.25 - 9.0mm. Designed for ...
Medicine Products: